Clinical Trials Directory
We are doing this study to find out if surgically removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing melanoma from coming back in the same area of the lymph node excision. We also want to learn more about the side effects of this type of surgery and how it can impact patients' quality of life.
In this study, people will get a new kind of eye transplant. They'll be randomly chosen (like flipping a coin) to get either a special treated cornea or a regular one. Doctors will check on them for 2 years after the transplant to see how they're doing and to watch for any side effects.
We are doing this study to evaluate an experimental technology called the Reprieve Decongestion Management System (the study device) for heart failure patients with fluid overload. The study device is designed to help people with heart failure feel better by removing extra fluid from their body quickly. The device is programmed to deliver an appropriate amount of medication at the right time to help people shed extra fluid through urination. We want to know if this device works better than the standard treatment. The standard treatment is to prescribe diuretics (medication to increase urination) at a specified dose and dosage schedule.
We are doing this study to examine genetic changes in your tumor that may contribute to resistance to immunotherapy. With this information, we hope to be able to identify new treatment methods as well as improve our ability to identify patients more likely to respond to immunotherapy.
We are doing this study to find out if an experimental drug called felzartamab (the study drug) is a safe and effective option for people who have had a kidney transplant and are experiencing antibody-mediated rejection (AMR). We want to know if this drug provides any helpful benefit.
We are doing this study to find out if an experimental drug called LY4337713 (the study drug) is a safe and effective option for people who have FAP-positive solid tumors. The study drug is a type of radiotherapy that is intended to target and attach only to FAP. The goal of targeted radiotherapy is to provide selective delivery of radiation doses that can destroy tumor cells.
This study has three parts. First is the screening phase, where doctors check if a person can join. Next is the treatment phase, where the person gets the study medicine and has an End of Treatment visit. Last is the long-term follow-up, where doctors watch the person’s health for a long time. This includes a safety check 30 days after treatment. A person may be in the study for up to 5 years. There are two groups in the study. People will be placed into a group by chance. One group will get the study medicine, and the other group will get chemotherapy chosen by the doctor. The study medicine is called Tovorafenib. It is used to treat certain brain tumors in children and young adults, especially a type called pediatric low-grade gliomas that have changes in the RAF or BRAF gene.
This study is for people with a kind of brain cancer called GBM. They will be placed into one of two treatment groups—either a regular treatment or a new one being tested. The study has two parts. In the first part, doctors choose treatments based on how well they are working for others with similar cancer. In the second part, treatments that look helpful are tested more closely. People in the study will have brain scans every 6 to 8 weeks to check the size of the tumor. They will also have blood tests, physical check-ups, and answer questions about how they feel. Some people may take tests to check their thinking and memory. Treatment will continue until the cancer gets worse or the side effects become too strong. Regular treatments include radiation and a medicine called temozolomide for people who are newly diagnosed. For people whose cancer has come back, the treatment is a chemotherapy medicine called lomustine.